Cancer Immunotherapy and Tumor Microenvironment Dynamics

Cancer immunotherapy harnesses the body’s own immune system to identify and eradicate malignant cells, transforming the treatment paradigm for many solid tumours and haematological malignancies. Central to successful immunotherapy is the tumour microenvironment (TME), a complex and dynamic ecosystem comprising cancer cells, stromal elements, infiltrating immune populations, vascular networks and an array of soluble mediators. Bidirectional interactions within this milieu dictate whether immune effector cells become activated or suppressed. Key mechanisms of immune escape include upregulation of checkpoint ligands, recruitment of suppressive myeloid and regulatory T-cell subsets, metabolic competition for nutrients and local secretion of immunomodulatory lipids such as prostaglandin E₂. Contemporary therapeutic strategies seek not only to block inhibitory pathways—most notably the PD-1/PD-L1 and CTLA-4 axes—but also to reprogramme the TME by combining checkpoint inhibitors with targeted agents, small‐molecule modulators and cellular therapies. Advances in spatial transcriptomics, single-cell sequencing and in vivo imaging have refined our understanding of spatiotemporal TME heterogeneity, guiding rational design of combination regimens. Globally, these efforts aim to extend durable responses beyond a minority of responsive patients, increase immunotherapy access and reduce toxicity through personalised approaches.

Research from Nature Portfolio

Recent studies have charted the evolution of immune checkpoint blockade from early conceptualisation to established clinical reality. Foundational work delineated the PD-1/PD-L1 pathway’s role in non-small cell lung cancer, demonstrating that ligand expression by tumour and stromal cells fosters an immunosuppressive niche reversible by specific monoclonal antibodies. These insights spurred rapid clinical translation, with pathway inhibitors now standard of care across multiple indications. A subsequent perspective on the field’s maturity highlighted critical challenges—primary resistance, immune-related adverse events and optimal sequencing with conventional therapies—and proposed a framework for next-generation immunomodulators. Emphasis was placed on integrated biomarker development, combination strategies to remodel a ‘cold’ microenvironment and the pursuit of neoantigen-driven personalised vaccines. Together, these contributions underscore a transition from single-agent checkpoint blockade towards sophisticated, multimodal regimens informed by mechanistic understanding of TME dynamics.

Cancer Immunotherapy and Tumor Microenvironment Dynamics publication trend

The graph below shows the total number of articles in cancer immunotherapy and tumor microenvironment dynamics across all publications each year (not limited to Nature Index journals).

Technical terms

Immune checkpoint blockade: Therapeutic inhibition of regulatory pathways (for example PD-1/PD-L1 or CTLA-4) to enhance T-cell-mediated tumour killing.

Tumour microenvironment (TME): The complex milieu of cancer cells, stromal cells, infiltrating immune populations and signalling molecules that surrounds and interacts with a tumour.

Prostaglandin E2 (PGE2): An eicosanoid lipid mediator produced in the TME that can suppress effector immune functions and promote inflammation-driven tumour growth.

Myeloid-derived suppressor cells (MDSCs): A heterogeneous population of immature myeloid cells that accumulate in tumours and inhibit T-cell activation through diverse mechanisms.

Cytotoxic T lymphocytes (CTLs): CD8⁺ T cells capable of recognising tumour antigens and directly inducing apoptosis in malignant cells.

References

1. KLF5 inhibition potentiates anti-PD1 efficacy by enhancing CD8+ T-cell-dependent antitumor immunity. Theranostics (2023).
2. Isorhamnetin and anti-PD-L1 antibody dual-functional mesoporous silica nanoparticles improve tumor immune microenvironment and inhibit YY1-mediated tumor progression. Journal of Nanobiotechnology (2023).
3. Immunotherapy: Reshape the Tumor Immune Microenvironment. Frontiers in Immunology (2022).
4. Development of PD-1/PD-L1 Pathway in Tumor Immune Microenvironment and Treatment for Non-Small Cell Lung Cancer. Scientific Reports (2015).
5. Cancer immunotherapy comes of age and looks for maturity. Nature Communications (2020).
6. Eicosanoids in Cancer: New Roles in Immunoregulation. Frontiers in Pharmacology (2020).